Unity Capex To Revenue from 2010 to 2024

UBX Stock  USD 1.21  0.02  1.68%   
Unity Biotechnology Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.47
Current Value
0.62
Quarterly Volatility
0.53493616
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.5 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 1.07. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Unity Biotechnology Correlation against competitors.
For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Latest Unity Biotechnology's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Unity Biotechnology over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Unity Biotechnology's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Unity Capex To Revenue Regression Statistics

Arithmetic Mean0.76
Geometric Mean0.41
Coefficient Of Variation70.16
Mean Deviation0.49
Median1.22
Standard Deviation0.53
Sample Variance0.29
Range1.1814
R-Value(0.74)
Mean Square Error0.14
R-Squared0.54
Significance0
Slope(0.09)
Total Sum of Squares4.01

Unity Capex To Revenue History

2024 0.62
2023 0.47
2022 0.41
2018 0.0408

About Unity Biotechnology Financial Statements

Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.47  0.62 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.